Sandoz News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

15.11.24	Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio (GlobeNewswire)
30.10.24	Sandoz reports third-quarter and nine-month 2024 sales (GlobeNewswire)
12.08.24	Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position (GlobeNewswire)
08.08.24	Sandoz reports second-quarter sales and half-year 2024 results (GlobeNewswire)
25.07.24	Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases (GlobeNewswire)
01.07.24	FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US (GlobeNewswire)
22.05.24	Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe (GlobeNewswire)
07.05.24	Sandoz reports first quarter 2024 sales (GlobeNewswire)
30.04.24	Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG (GlobeNewswire)
30.04.24	Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars (GlobeNewswire)
22.04.24	Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering (GlobeNewswire)
21.03.24	Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines (GlobeNewswire)
05.03.24	Sandoz receives FDA approval for first and only denosumab biosimilars (GlobeNewswire)
05.03.24	Sandoz announces nominations to the Board of Directors and leadership change (GlobeNewswire)
04.03.24	Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market (GlobeNewswire)
29.02.24	Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs (GlobeNewswire)
01.02.24	Sandoz announces changes in the Board of Directors (GlobeNewswire)
31.01.24	Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany (GlobeNewswire)
22.01.24	Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market (GlobeNewswire)
21.11.23	Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care (GlobeNewswire)
08.11.23	Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds (GlobeNewswire)
26.10.23	Sandoz successfully issues CHF 750 million in inaugural bonds (GlobeNewswire)
24.10.23	Sandoz reports year-to-date sales for the first nine months of 2023 (GlobeNewswire)
04.10.23	Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		SIX-Handel: SLI zeigt sich zum Ende des Freitagshandels fester
22.11.24		Börse Zürich: SLI liegt am Freitagmittag im Plus
22.11.24		Starker Wochentag in Zürich: SLI liegt zum Start im Plus
21.11.24		Gewinne in Zürich: So performt der SLI am Mittag
20.11.24		Schwacher Wochentag in Zürich: SLI präsentiert sich schwächer
20.11.24		Börse Zürich: Börsianer lassen SLI mittags steigen
19.11.24		Handel in Zürich: SLI zum Start mit Gewinnen
18.11.24		Zuversicht in Zürich: Letztendlich Pluszeichen im SLI